Since the revised EU Pharmacovigilance legislation came into force in 2012, it has become a statutory requirement for pharmaceutical companies to produce risk management plans (RMPs) for a broad range of medicines. The DSRU team is heavily involved in both advising on and conducting studies which are part of RMPs. In addition, our team has experience in conducting studies to monitor the effectiveness of risk management measures. Scroll through the menu below to see the breadth of our capabilities.

Contact Info

Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, U.K.

Phone: +44 (0)23 80 40 86 00

Recent Posts